LifeMD Q2 FY26 adjusted EBITDA loss widens to $3.5 million; revenue falls to $47.3 million

• LifeMD posted Q2 revenue of $47.3 million, down 3.5% year-over-year; GAAP net loss attributable to common stockholders widened to $7.9 million.
• Adjusted EBITDA swung to a loss of about $3.5 million from a profit of about $3.9 million a year earlier; gross margin rose 3 percentage points to about 89%.
• Active subscribers climbed 20% year-over-year to about 356,000; weight management subscribers rose to about 108,000 from just under 100,000 at Q1 end.
• About 95% of new weight management patients started on branded GLP-1 therapies, as the company neared the end of its shift away from compounded GLP-1s.
• LifeMD cut full-year guidance to revenue of $205.5 million-$212.5 million and adjusted EBITDA of negative $6 million to breakeven; Q3 revenue seen at $48 million-$51 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LifeMD Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608051611PRIMZONEFULLFEED9804576) on August 05, 2026, and is solely responsible for the information contained therein.